SEHK:1093Pharmaceuticals
Will New Depression and Metabolic Trial Approvals Change CSPC Pharmaceutical Group's (SEHK:1093) Narrative?
In late 2025, CSPC Pharmaceutical Group announced multiple regulatory approvals in the U.S. and China to begin clinical trials for innovative therapies targeting major depressive disorder, obesity and overweight with comorbidities, and complement-mediated diseases such as IgA nephropathy.
By advancing a 5-HT2A agonist without hallucination risk, a dual-biased GLP-1/GIP agonist, and an ultra-long-acting C5 siRNA, CSPC is pivoting its pipeline toward high-demand areas where existing treatment...